Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;10(3):e587.
doi: 10.1002/iid3.587. Epub 2022 Jan 14.

Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia

Amani H Yamani  1 , Basem M Alraddadi  1 , Reem S Almaghrabi  2 , Afnan A Amer  1 , Fatimah S Mehdawi  3 , Mohammed A Al-Hamzi  1 , Meshari S Aldajani  4 , Majda S Alattas  5 , Aiman M Elsaed Ramadan  6 , Ghassan Y Wali  1 , Abeer N Alshukairi  1   7 , Abbas Al Mutair  8   9   10
Affiliations

Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia

Amani H Yamani et al. Immun Inflamm Dis. 2022 Mar.

Abstract

Background: Tocilizumab was studied to reduce cytokine syndrome in patients with severe COVID-19 pneumonia in solid organ transplant (SOT) recipients with conflicting results. We aim to study the early use of tocilizumab in SOT with COVID-19 pneumonia on low flow oxygen.

Methods: This is a retrospective cohort study that was conducted in two transplant centers in Saudi Arabia among 46 SOT with COVID-19 comparing 21 patients who received tocilizumab to 25 patients who received standard of care. Their clinical characteristics and outcomes were described.

Results: Compared to patients who received standard of care, patients in the tocilizumab group were older (60.2 ± 12.8 vs. 48.6 ± 12.3, p = .003), had higher ferritin (862.1 ± 919.1 vs. 414 ± 447.3, p = .025) and C-reactive protein (CRP) (85 ± 83.1 vs. 42.9 ± 57.3, p = .012). More patients in the tocilizumab group required high flow oxygen (38.1% vs. 8.0%, p = .028) compared to patients on standard of care. There were no differences in mortality or mechanical ventilation requirement. Hospital stay was significantly shorter in the tocilizumab group than the standard of care group (9.6 ± 7.4 vs. 20.7 ± 11.7, p < .001).

Conclusions: Early use of tocilizumab in SOT was associated with a shorter hospital stay. There was no difference in mortality rate and the requirement for mechanical ventilation in both groups.

Keywords: COVID-19; SOT; cytokine syndrome; tocilizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflict of interests.

References

    1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270‐273. 10.1038/s41586-020-2012-7 - DOI - PMC - PubMed
    1. Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome‐related coronavirus: classifying 2019‐nCoV and naming it SARS‐CoV‐2. Nat Microbiol. 2020;5:536‐544. 10.1038/s41564-020-0695-z - DOI - PMC - PubMed
    1. Alhazzani W, Al‐Suwaidan F, Al Aseri Z, et al. The Saudi critical care society clinical practice guidelines on the management of COVID‐19 patients in the intensive care unit. Saudi Crit Care J. 2020;4:27. 10.4103/sccj.sccj_15_20 - DOI
    1. Al‐Omari A, Alhuqbani WN, Zaidi ARZ, et al. Clinical characteristics of non‐intensive care unit COVID‐19 patients in Saudi Arabia: a descriptive cross‐sectional study. J Infect Public Health. 2020;13:1639‐1644. 10.1016/j.jiph.2020.09.003 - DOI - PMC - PubMed
    1. Al Mutair A, Alhumaid S, Alhuqbani WN, et al. Clinical, epidemiological, and laboratory characteristics of mild‐to‐moderate COVID‐19 patients in Saudi Arabia: an observational cohort study. Eur J Med Res. 2020;25:61. 10.1186/s40001-020-00462-x - DOI - PMC - PubMed

Substances